Dermatology Devices Market Size Will Achieve 11.9% CAGR From 2019 To 2025
The global dermatology devices market size is expected to reach USD 20 billion by 2025, at a CAGR of 11.9% during the forecast period 2019 to 2025.
On the dermatology devices market is a detailed analysis of the market sphere and provides details pertaining to Industry Tactics, Evolving Technologies, Key Companies, Growth Rate, Business Competitors, and Forecast by 2025. The report contains sufficient information about the various segments of the market and highlights their important aspects.
Europe dermatology devices market accounted for around 27% revenue share in 2018 and is calculated to witness a significant CAGR by 2025. The high adoption of technically advanced dermatology devices, well-established healthcare infrastructure will enhance the regional market growth. Moreover, high awareness about advanced skin treatment and diagnosis, growing demand for facial surgeries in the region along will spur Europe market.
Endorsed as an integral vertical of medical equipment space, the dermatology devices market has been of late, providing lucrative growth opportunities to the investors to exploit economies of scale. This testament is validated from the increasing attempts by the industry giants like Ambicare, Biolitec, Alma Lasers, and various others, that have been working to come up with innovative products.
To access a sample copy of the “Dermatology Devices Market” report in detail along with the table of contents@ https://www.gminsights.com/request-sample/detail/2644
Not to mention, rising geriatric population, high frequency of obesity, enhancing healthcare expenditures, and high economic affluences have been proliferating the industry outlook. However, umpteen adverse effects of skin treatments and high cost pertaining to the dermatology procedures would likely hinder the market growth in the upcoming years.
Dermatology Devices Market report is an all-inclusive document, compiled and designed to provide best-in-class research, insightful analysis and accurate quantitative data. The coverage of this research is the most extensive when compared to other similar studies available on Dermatology Devices Market. The industry ecosystem information presented in this report is next-to-none and aims to address all stakeholders of the industry, irrespective of their size and business function.
One of the prudent rationales behind the escalated growth of dermatology devices industry is the high penetration of treatment devices. This segmental growth can be aptly credited to the surging advancements and mounting awareness regarding availability of superior quality treatment devices. Expediting concerns amongst females pertaining to the facial appearance are further stimulating the market growth across the segment.
Treatment dermatology devices segment is expected to register CAGR of 12.5% over the forecast period. The growing adoption of technically advanced treatment is substantially contributing towards high share of segment in the dermatology devices market.
In fact, the treatment devices segment held a significant business share of approximately 4 billion in 2018 and is projected to develop at a growth rate of 12.5 per cent through 2025.
Bifurcated further, the treatment devices segment is predominated by the lasers segment which is estimated to accrue hefty proceeds over the forecast period. Increasing deployment of laser therapy for myriad skin treatments including removal of unwanted hairs, fine lines, wrinkles, and age spots, have laid a positive influence on the treatment devices market.
Know about Market growth in New Research and its Top growing factors by Key Companies like
Gen, Alma Lasers, Ambicare, AMD Global Telemedicine, Inc., Beijing Toplaser Technology Co. Ltd., biolitec AG, Cortex Technology, Cutera, Dansys Group, Ellipse (CANDELA CORPORATION), Genesis Biosystems, Inc., HEINE Optotechnik GmbH & Co. KG, Hologic, Inc., Image Derm Inc., Leader Healthcare India, Lumenis, Michelson Diagnostics (Michelson Diagnostics Ltd), Solta Medical (Bausch Health Companies Inc.)